Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 2

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 2
---
 pre-funded warrants to support entry into an Intellectual Property License Agreement (the “License Agreement”) with WuXi Biologics (Shanghai FX) Co., Ltd. (“WuXi Biologics”) for                 
 exclusive rights to certain patents and know-how pertaining to WuXi Biologics’ pre-clinical antibody                                                                                                        |

| drug conjugate (“ADC”) programs leveraging Hangzhou DAC Biotechnology Co., Ltd.’s (“Hangzhou DAC”) linker-payload technology targeting each of Mucin-16 (“MUC16”), Protein Tyrosine Kinase 7 (“PTK7”) and Seizure Related 6 Homolog (“SEZ6”) (collectively, the “ADC Programs”). |

| 3. | Equity Plan Increase Proposal. To approve an amendment to the Aadi Bioscience, Inc. 2021 Equity                                                                                                                       
 Incentive Plan (the “2021 Plan”) to (i) increase the shares available for issuance under the 2021 Plan by 6,300,000 shares from 2,000,284 shares to 8,300,284 shares and (ii) increase the 2021 Plan’s default annual 
 automatic share reserve increase occurring on January 1 of each year from 4% of outstanding shares on the last day of the immediately preceding fiscal year to 5% (the “Equity Plan Increase Proposal”).              |

| 4. | Non-Binding Advisory Vote on Golden Parachutes Proposal. To                                                                                                                                                  
 approve, on a non-binding, advisory basis, certain compensation that will or may become payable to our named executive officers in connection with the Divestiture (the “Non-Binding Advisory Vote on Golden 
 Parachutes Proposal”).                                                                                                                                                                                       |

| 5. | Adjournment Proposal. To approve one or more adjournments of the Special Meeting, if necessary or                                                                                                                                        
 appropriate and to the extent permitted by the Divestiture Agreement, to solicit additional proxies if there are insufficient votes at the time of the Special Meeting to approve the Divestiture Proposal (the “Adjournment Proposal”). |

Whether or not you attend the Special Meeting, it is important that your shares be represented and voted at the meeting. Therefore, we urge you to promptly vote and submit your proxy via the Internet, by phone or by mail (by signing, dating and returning the enclosed proxy card in the enclosed envelope). If you decide to attend the Special Meeting virtually, you will be able to change your vote, revoke your proxy or vote electronically